Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ITAC: hIVIG in Hospitalized COVID-19
NCT04546581Phase 3Completed
- Sponsor
- University of Minnesota
- Start
- Oct 2020
- Primary completion
- May 2021
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 7
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing hIVIG + SOC with Placebo + SOC (2 arms). Primary endpoints: Ordinal Outcome Scale based on Clinical Status at Day 7 and Death, SAE or Grade 3 or 4 Events at Day 7. Started Oct 2020; status: completed.
02
Drugs
CoviGlobulin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04546581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04546581.